好酸球増加症候群薬の世界市場（～2026年）

• 英文タイトル：Global Hypereosinophilic Syndrome Drug Market Insights and Forecast to 2026

• レポートコード：MRC2-11QY01514 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は好酸球増加症候群薬のグローバル市場について調査・分析したレポートです。種類別（ベンラリズマブ、ダサチニブ、デクスプラミペキソール二塩酸塩、メポリズマブ、その他）市場規模、用途別（研究センター、病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別好酸球増加症候群薬の競争状況、市場シェア ・世界の好酸球増加症候群薬市場：種類別市場規模 2015年-2020年（ベンラリズマブ、ダサチニブ、デクスプラミペキソール二塩酸塩、メポリズマブ、その他） ・世界の好酸球増加症候群薬市場：種類別市場規模予測 2021年-2026年（ベンラリズマブ、ダサチニブ、デクスプラミペキソール二塩酸塩、メポリズマブ、その他） ・世界の好酸球増加症候群薬市場：用途別市場規模 2015年-2020年（研究センター、病院、クリニック） ・世界の好酸球増加症候群薬市場：用途別市場規模予測 2021年-2026年（研究センター、病院、クリニック） ・北米の好酸球増加症候群薬市場分析：米国、カナダ ・ヨーロッパの好酸球増加症候群薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの好酸球増加症候群薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の好酸球増加症候群薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの好酸球増加症候群薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Bristol-Myers Squibb Co、GlaxoSmithKline Plc、Knopp Biosciences LLC、Kyowa Hakko Kirin Co Ltd、Stemline Therapeutics Inc ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Market Analysis and Insights: Global Hypereosinophilic Syndrome Drug Market
The global Hypereosinophilic Syndrome Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Hypereosinophilic Syndrome Drug Scope and Market Size
Hypereosinophilic Syndrome Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hypereosinophilic Syndrome Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Hypereosinophilic Syndrome Drug market is segmented into
Benralizumab
Dasatinib
Dexpramipexole Dihydrochloride
Mepolizumab
Others

Segment by Application, the Hypereosinophilic Syndrome Drug market is segmented into
Research Center
Hospital
Clinic

Regional and Country-level Analysis
The Hypereosinophilic Syndrome Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Hypereosinophilic Syndrome Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Hypereosinophilic Syndrome Drug Market Share Analysis
Hypereosinophilic Syndrome Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Hypereosinophilic Syndrome Drug business, the date to enter into the Hypereosinophilic Syndrome Drug market, Hypereosinophilic Syndrome Drug product introduction, recent developments, etc.

The major vendors covered:
Bristol-Myers Squibb Co
GlaxoSmithKline Plc
Knopp Biosciences LLC
Kyowa Hakko Kirin Co Ltd
Stemline Therapeutics Inc
…

レポート目次

---

1 Study Coverage
1.1 Hypereosinophilic Syndrome Drug Product Introduction
1.2 Market Segments
1.3 Key Hypereosinophilic Syndrome Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Hypereosinophilic Syndrome Drug Market Size Growth Rate by Type
1.4.2 Benralizumab
1.4.3 Dasatinib
1.4.4 Dexpramipexole Dihydrochloride
1.4.5 Mepolizumab
1.4.6 Others
1.5 Market by Application
1.5.1 Global Hypereosinophilic Syndrome Drug Market Size Growth Rate by Application
1.5.2 Research Center
1.5.3 Hospital
1.5.4 Clinic
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Hypereosinophilic Syndrome Drug Market Size, Estimates and Forecasts
2.1.1 Global Hypereosinophilic Syndrome Drug Revenue 2015-2026
2.1.2 Global Hypereosinophilic Syndrome Drug Sales 2015-2026
2.2 Global Hypereosinophilic Syndrome Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Hypereosinophilic Syndrome Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Hypereosinophilic Syndrome Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Hypereosinophilic Syndrome Drug Competitor Landscape by Players
3.1 Hypereosinophilic Syndrome Drug Sales by Manufacturers
3.1.1 Hypereosinophilic Syndrome Drug Sales by Manufacturers (2015-2020)
3.1.2 Hypereosinophilic Syndrome Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Hypereosinophilic Syndrome Drug Revenue by Manufacturers
3.2.1 Hypereosinophilic Syndrome Drug Revenue by Manufacturers (2015-2020)
3.2.2 Hypereosinophilic Syndrome Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Hypereosinophilic Syndrome Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Hypereosinophilic Syndrome Drug Revenue in 2019
3.2.5 Global Hypereosinophilic Syndrome Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Hypereosinophilic Syndrome Drug Price by Manufacturers
3.4 Hypereosinophilic Syndrome Drug Manufacturing Base Distribution, Product Types
3.4.1 Hypereosinophilic Syndrome Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Hypereosinophilic Syndrome Drug Product Type
3.4.3 Date of International Manufacturers Enter into Hypereosinophilic Syndrome Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Hypereosinophilic Syndrome Drug Market Size by Type (2015-2020)
4.1.1 Global Hypereosinophilic Syndrome Drug Sales by Type (2015-2020)
4.1.2 Global Hypereosinophilic Syndrome Drug Revenue by Type (2015-2020)
4.1.3 Hypereosinophilic Syndrome Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Hypereosinophilic Syndrome Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Hypereosinophilic Syndrome Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Hypereosinophilic Syndrome Drug Revenue Forecast by Type (2021-2026)
4.2.3 Hypereosinophilic Syndrome Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Hypereosinophilic Syndrome Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Hypereosinophilic Syndrome Drug Market Size by Application (2015-2020)
5.1.1 Global Hypereosinophilic Syndrome Drug Sales by Application (2015-2020)
5.1.2 Global Hypereosinophilic Syndrome Drug Revenue by Application (2015-2020)
5.1.3 Hypereosinophilic Syndrome Drug Price by Application (2015-2020)
5.2 Hypereosinophilic Syndrome Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Hypereosinophilic Syndrome Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Hypereosinophilic Syndrome Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Hypereosinophilic Syndrome Drug Price Forecast by Application (2021-2026)

6 North America
6.1 North America Hypereosinophilic Syndrome Drug by Country
6.1.1 North America Hypereosinophilic Syndrome Drug Sales by Country
6.1.2 North America Hypereosinophilic Syndrome Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Hypereosinophilic Syndrome Drug Market Facts & Figures by Type
6.3 North America Hypereosinophilic Syndrome Drug Market Facts & Figures by Application

7 Europe
7.1 Europe Hypereosinophilic Syndrome Drug by Country
7.1.1 Europe Hypereosinophilic Syndrome Drug Sales by Country
7.1.2 Europe Hypereosinophilic Syndrome Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Hypereosinophilic Syndrome Drug Market Facts & Figures by Type
7.3 Europe Hypereosinophilic Syndrome Drug Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Hypereosinophilic Syndrome Drug by Region
8.1.1 Asia Pacific Hypereosinophilic Syndrome Drug Sales by Region
8.1.2 Asia Pacific Hypereosinophilic Syndrome Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Hypereosinophilic Syndrome Drug Market Facts & Figures by Type
8.3 Asia Pacific Hypereosinophilic Syndrome Drug Market Facts & Figures by Application

9 Latin America
9.1 Latin America Hypereosinophilic Syndrome Drug by Country
9.1.1 Latin America Hypereosinophilic Syndrome Drug Sales by Country
9.1.2 Latin America Hypereosinophilic Syndrome Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Hypereosinophilic Syndrome Drug Market Facts & Figures by Type
9.3 Central & South America Hypereosinophilic Syndrome Drug Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Hypereosinophilic Syndrome Drug by Country
10.1.1 Middle East and Africa Hypereosinophilic Syndrome Drug Sales by Country
10.1.2 Middle East and Africa Hypereosinophilic Syndrome Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Hypereosinophilic Syndrome Drug Market Facts & Figures by Type
10.3 Middle East and Africa Hypereosinophilic Syndrome Drug Market Facts & Figures by Application

11 Company Profiles
11.1 Bristol-Myers Squibb Co
11.1.1 Bristol-Myers Squibb Co Corporation Information
11.1.2 Bristol-Myers Squibb Co Description and Business Overview
11.1.3 Bristol-Myers Squibb Co Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Bristol-Myers Squibb Co Hypereosinophilic Syndrome Drug Products Offered
11.1.5 Bristol-Myers Squibb Co Related Developments
11.2 GlaxoSmithKline Plc
11.2.1 GlaxoSmithKline Plc Corporation Information
11.2.2 GlaxoSmithKline Plc Description and Business Overview
11.2.3 GlaxoSmithKline Plc Sales, Revenue and Gross Margin (2015-2020)
11.2.4 GlaxoSmithKline Plc Hypereosinophilic Syndrome Drug Products Offered
11.2.5 GlaxoSmithKline Plc Related Developments
11.3 Knopp Biosciences LLC
11.3.1 Knopp Biosciences LLC Corporation Information
11.3.2 Knopp Biosciences LLC Description and Business Overview
11.3.3 Knopp Biosciences LLC Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Knopp Biosciences LLC Hypereosinophilic Syndrome Drug Products Offered
11.3.5 Knopp Biosciences LLC Related Developments
11.4 Kyowa Hakko Kirin Co Ltd
11.4.1 Kyowa Hakko Kirin Co Ltd Corporation Information
11.4.2 Kyowa Hakko Kirin Co Ltd Description and Business Overview
11.4.3 Kyowa Hakko Kirin Co Ltd Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Kyowa Hakko Kirin Co Ltd Hypereosinophilic Syndrome Drug Products Offered
11.4.5 Kyowa Hakko Kirin Co Ltd Related Developments
11.5 Stemline Therapeutics Inc
11.5.1 Stemline Therapeutics Inc Corporation Information
11.5.2 Stemline Therapeutics Inc Description and Business Overview
11.5.3 Stemline Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Stemline Therapeutics Inc Hypereosinophilic Syndrome Drug Products Offered
11.5.5 Stemline Therapeutics Inc Related Developments
11.1 Bristol-Myers Squibb Co
11.1.1 Bristol-Myers Squibb Co Corporation Information
11.1.2 Bristol-Myers Squibb Co Description and Business Overview
11.1.3 Bristol-Myers Squibb Co Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Bristol-Myers Squibb Co Hypereosinophilic Syndrome Drug Products Offered
11.1.5 Bristol-Myers Squibb Co Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Hypereosinophilic Syndrome Drug Market Estimates and Projections by Region
12.1.1 Global Hypereosinophilic Syndrome Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Hypereosinophilic Syndrome Drug Revenue Forecast by Regions 2021-2026
12.2 North America Hypereosinophilic Syndrome Drug Market Size Forecast (2021-2026)
12.2.1 North America: Hypereosinophilic Syndrome Drug Sales Forecast (2021-2026)
12.2.2 North America: Hypereosinophilic Syndrome Drug Revenue Forecast (2021-2026)
12.2.3 North America: Hypereosinophilic Syndrome Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Hypereosinophilic Syndrome Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Hypereosinophilic Syndrome Drug Sales Forecast (2021-2026)
12.3.2 Europe: Hypereosinophilic Syndrome Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Hypereosinophilic Syndrome Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Hypereosinophilic Syndrome Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Hypereosinophilic Syndrome Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Hypereosinophilic Syndrome Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Hypereosinophilic Syndrome Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Hypereosinophilic Syndrome Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Hypereosinophilic Syndrome Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Hypereosinophilic Syndrome Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Hypereosinophilic Syndrome Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Hypereosinophilic Syndrome Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Hypereosinophilic Syndrome Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Hypereosinophilic Syndrome Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Hypereosinophilic Syndrome Drug Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Hypereosinophilic Syndrome Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Hypereosinophilic Syndrome Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Hypereosinophilic Syndrome Drug Market Segments
Table 2. Ranking of Global Top Hypereosinophilic Syndrome Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Hypereosinophilic Syndrome Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Benralizumab
Table 5. Major Manufacturers of Dasatinib
Table 6. Major Manufacturers of Dexpramipexole Dihydrochloride
Table 7. Major Manufacturers of Mepolizumab
Table 8. Major Manufacturers of Others
Table 9. Global Hypereosinophilic Syndrome Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 10. Global Hypereosinophilic Syndrome Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 11. Global Hypereosinophilic Syndrome Drug Sales by Regions 2015-2020 (K Pcs)
Table 12. Global Hypereosinophilic Syndrome Drug Sales Market Share by Regions (2015-2020)
Table 13. Global Hypereosinophilic Syndrome Drug Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Hypereosinophilic Syndrome Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 15. Global Hypereosinophilic Syndrome Drug Sales Share by Manufacturers (2015-2020)
Table 16. Global Hypereosinophilic Syndrome Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Hypereosinophilic Syndrome Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hypereosinophilic Syndrome Drug as of 2019)
Table 18. Hypereosinophilic Syndrome Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Hypereosinophilic Syndrome Drug Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Hypereosinophilic Syndrome Drug Price (2015-2020) (USD/Pcs)
Table 21. Hypereosinophilic Syndrome Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Hypereosinophilic Syndrome Drug Product Type
Table 23. Date of International Manufacturers Enter into Hypereosinophilic Syndrome Drug Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Hypereosinophilic Syndrome Drug Sales by Type (2015-2020) (K Pcs)
Table 26. Global Hypereosinophilic Syndrome Drug Sales Share by Type (2015-2020)
Table 27. Global Hypereosinophilic Syndrome Drug Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Hypereosinophilic Syndrome Drug Revenue Share by Type (2015-2020)
Table 29. Hypereosinophilic Syndrome Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 30. Global Hypereosinophilic Syndrome Drug Sales by Application (2015-2020) (K Pcs)
Table 31. Global Hypereosinophilic Syndrome Drug Sales Share by Application (2015-2020)
Table 32. North America Hypereosinophilic Syndrome Drug Sales by Country (2015-2020) (K Pcs)
Table 33. North America Hypereosinophilic Syndrome Drug Sales Market Share by Country (2015-2020)
Table 34. North America Hypereosinophilic Syndrome Drug Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Hypereosinophilic Syndrome Drug Revenue Market Share by Country (2015-2020)
Table 36. North America Hypereosinophilic Syndrome Drug Sales by Type (2015-2020) (K Pcs)
Table 37. North America Hypereosinophilic Syndrome Drug Sales Market Share by Type (2015-2020)
Table 38. North America Hypereosinophilic Syndrome Drug Sales by Application (2015-2020) (K Pcs)
Table 39. North America Hypereosinophilic Syndrome Drug Sales Market Share by Application (2015-2020)
Table 40. Europe Hypereosinophilic Syndrome Drug Sales by Country (2015-2020) (K Pcs)
Table 41. Europe Hypereosinophilic Syndrome Drug Sales Market Share by Country (2015-2020)
Table 42. Europe Hypereosinophilic Syndrome Drug Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Hypereosinophilic Syndrome Drug Revenue Market Share by Country (2015-2020)
Table 44. Europe Hypereosinophilic Syndrome Drug Sales by Type (2015-2020) (K Pcs)
Table 45. Europe Hypereosinophilic Syndrome Drug Sales Market Share by Type (2015-2020)
Table 46. Europe Hypereosinophilic Syndrome Drug Sales by Application (2015-2020) (K Pcs)
Table 47. Europe Hypereosinophilic Syndrome Drug Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Hypereosinophilic Syndrome Drug Sales by Region (2015-2020) (K Pcs)
Table 49. Asia Pacific Hypereosinophilic Syndrome Drug Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Hypereosinophilic Syndrome Drug Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Hypereosinophilic Syndrome Drug Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Hypereosinophilic Syndrome Drug Sales by Type (2015-2020) (K Pcs)
Table 53. Asia Pacific Hypereosinophilic Syndrome Drug Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Hypereosinophilic Syndrome Drug Sales by Application (2015-2020) (K Pcs)
Table 55. Asia Pacific Hypereosinophilic Syndrome Drug Sales Market Share by Application (2015-2020)
Table 56. Latin America Hypereosinophilic Syndrome Drug Sales by Country (2015-2020) (K Pcs)
Table 57. Latin America Hypereosinophilic Syndrome Drug Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Hypereosinophilic Syndrome Drug Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Hypereosinophilic Syndrome Drug Revenue Market Share by Country (2015-2020)
Table 60. Latin America Hypereosinophilic Syndrome Drug Sales by Type (2015-2020) (K Pcs)
Table 61. Latin America Hypereosinophilic Syndrome Drug Sales Market Share by Type (2015-2020)
Table 62. Latin America Hypereosinophilic Syndrome Drug Sales by Application (2015-2020) (K Pcs)
Table 63. Latin America Hypereosinophilic Syndrome Drug Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Hypereosinophilic Syndrome Drug Sales by Country (2015-2020) (K Pcs)
Table 65. Middle East and Africa Hypereosinophilic Syndrome Drug Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Hypereosinophilic Syndrome Drug Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Hypereosinophilic Syndrome Drug Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Hypereosinophilic Syndrome Drug Sales by Type (2015-2020) (K Pcs)
Table 69. Middle East and Africa Hypereosinophilic Syndrome Drug Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Hypereosinophilic Syndrome Drug Sales by Application (2015-2020) (K Pcs)
Table 71. Middle East and Africa Hypereosinophilic Syndrome Drug Sales Market Share by Application (2015-2020)
Table 72. Bristol-Myers Squibb Co Corporation Information
Table 73. Bristol-Myers Squibb Co Description and Major Businesses
Table 74. Bristol-Myers Squibb Co Hypereosinophilic Syndrome Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 75. Bristol-Myers Squibb Co Product
Table 76. Bristol-Myers Squibb Co Recent Development
Table 77. GlaxoSmithKline Plc Corporation Information
Table 78. GlaxoSmithKline Plc Description and Major Businesses
Table 79. GlaxoSmithKline Plc Hypereosinophilic Syndrome Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 80. GlaxoSmithKline Plc Product
Table 81. GlaxoSmithKline Plc Recent Development
Table 82. Knopp Biosciences LLC Corporation Information
Table 83. Knopp Biosciences LLC Description and Major Businesses
Table 84. Knopp Biosciences LLC Hypereosinophilic Syndrome Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 85. Knopp Biosciences LLC Product
Table 86. Knopp Biosciences LLC Recent Development
Table 87. Kyowa Hakko Kirin Co Ltd Corporation Information
Table 88. Kyowa Hakko Kirin Co Ltd Description and Major Businesses
Table 89. Kyowa Hakko Kirin Co Ltd Hypereosinophilic Syndrome Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 90. Kyowa Hakko Kirin Co Ltd Product
Table 91. Kyowa Hakko Kirin Co Ltd Recent Development
Table 92. Stemline Therapeutics Inc Corporation Information
Table 93. Stemline Therapeutics Inc Description and Major Businesses
Table 94. Stemline Therapeutics Inc Hypereosinophilic Syndrome Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 95. Stemline Therapeutics Inc Product
Table 96. Stemline Therapeutics Inc Recent Development
Table 97. Global Hypereosinophilic Syndrome Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 98. Global Hypereosinophilic Syndrome Drug Sales Market Share Forecast by Regions (2021-2026)
Table 99. Global Hypereosinophilic Syndrome Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 100. Global Hypereosinophilic Syndrome Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 101. North America: Hypereosinophilic Syndrome Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 102. North America: Hypereosinophilic Syndrome Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 103. Europe: Hypereosinophilic Syndrome Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 104. Europe: Hypereosinophilic Syndrome Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 105. Asia Pacific: Hypereosinophilic Syndrome Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 106. Asia Pacific: Hypereosinophilic Syndrome Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 107. Latin America: Hypereosinophilic Syndrome Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 108. Latin America: Hypereosinophilic Syndrome Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 109. Middle East and Africa: Hypereosinophilic Syndrome Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 110. Middle East and Africa: Hypereosinophilic Syndrome Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 111. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 112. Key Challenges
Table 113. Market Risks
Table 114. Main Points Interviewed from Key Hypereosinophilic Syndrome Drug Players
Table 115. Hypereosinophilic Syndrome Drug Customers List
Table 116. Hypereosinophilic Syndrome Drug Distributors List
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Hypereosinophilic Syndrome Drug Product Picture
Figure 2. Global Hypereosinophilic Syndrome Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Benralizumab Product Picture
Figure 4. Dasatinib Product Picture
Figure 5. Dexpramipexole Dihydrochloride Product Picture
Figure 6. Mepolizumab Product Picture
Figure 7. Others Product Picture
Figure 8. Global Hypereosinophilic Syndrome Drug Sales Market Share by Application in 2020 & 2026
Figure 9. Research Center
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Hypereosinophilic Syndrome Drug Report Years Considered
Figure 13. Global Hypereosinophilic Syndrome Drug Market Size 2015-2026 (US$ Million)
Figure 14. Global Hypereosinophilic Syndrome Drug Sales 2015-2026 (K Pcs)
Figure 15. Global Hypereosinophilic Syndrome Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Hypereosinophilic Syndrome Drug Sales Market Share by Region (2015-2020)
Figure 17. Global Hypereosinophilic Syndrome Drug Sales Market Share by Region in 2019
Figure 18. Global Hypereosinophilic Syndrome Drug Revenue Market Share by Region (2015-2020)
Figure 19. Global Hypereosinophilic Syndrome Drug Revenue Market Share by Region in 2019
Figure 20. Global Hypereosinophilic Syndrome Drug Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by Hypereosinophilic Syndrome Drug Revenue in 2019
Figure 22. Hypereosinophilic Syndrome Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global Hypereosinophilic Syndrome Drug Sales Market Share by Type (2015-2020)
Figure 24. Global Hypereosinophilic Syndrome Drug Sales Market Share by Type in 2019
Figure 25. Global Hypereosinophilic Syndrome Drug Revenue Market Share by Type (2015-2020)
Figure 26. Global Hypereosinophilic Syndrome Drug Revenue Market Share by Type in 2019
Figure 27. Global Hypereosinophilic Syndrome Drug Market Share by Price Range (2015-2020)
Figure 28. Global Hypereosinophilic Syndrome Drug Sales Market Share by Application (2015-2020)
Figure 29. Global Hypereosinophilic Syndrome Drug Sales Market Share by Application in 2019
Figure 30. Global Hypereosinophilic Syndrome Drug Revenue Market Share by Application (2015-2020)
Figure 31. Global Hypereosinophilic Syndrome Drug Revenue Market Share by Application in 2019
Figure 32. North America Hypereosinophilic Syndrome Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 33. North America Hypereosinophilic Syndrome Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 34. North America Hypereosinophilic Syndrome Drug Sales Market Share by Country in 2019
Figure 35. North America Hypereosinophilic Syndrome Drug Revenue Market Share by Country in 2019
Figure 36. U.S. Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 37. U.S. Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Canada Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. Canada Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. North America Hypereosinophilic Syndrome Drug Market Share by Type in 2019
Figure 41. North America Hypereosinophilic Syndrome Drug Market Share by Application in 2019
Figure 42. Europe Hypereosinophilic Syndrome Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 43. Europe Hypereosinophilic Syndrome Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. Europe Hypereosinophilic Syndrome Drug Sales Market Share by Country in 2019
Figure 45. Europe Hypereosinophilic Syndrome Drug Revenue Market Share by Country in 2019
Figure 46. Germany Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. Germany Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. France Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. France Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. U.K. Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. U.K. Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Italy Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Italy Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Russia Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Russia Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Europe Hypereosinophilic Syndrome Drug Market Share by Type in 2019
Figure 57. Europe Hypereosinophilic Syndrome Drug Market Share by Application in 2019
Figure 58. Asia Pacific Hypereosinophilic Syndrome Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 59. Asia Pacific Hypereosinophilic Syndrome Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 60. Asia Pacific Hypereosinophilic Syndrome Drug Sales Market Share by Region in 2019
Figure 61. Asia Pacific Hypereosinophilic Syndrome Drug Revenue Market Share by Region in 2019
Figure 62. China Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. China Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Japan Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. Japan Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. South Korea Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. South Korea Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. India Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. India Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Australia Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Australia Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Taiwan Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Taiwan Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Indonesia Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Indonesia Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Thailand Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Thailand Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Malaysia Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Malaysia Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Philippines Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Philippines Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Vietnam Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Vietnam Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Asia Pacific Hypereosinophilic Syndrome Drug Market Share by Type in 2019
Figure 85. Asia Pacific Hypereosinophilic Syndrome Drug Market Share by Application in 2019
Figure 86. Latin America Hypereosinophilic Syndrome Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 87. Latin America Hypereosinophilic Syndrome Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 88. Latin America Hypereosinophilic Syndrome Drug Sales Market Share by Country in 2019
Figure 89. Latin America Hypereosinophilic Syndrome Drug Revenue Market Share by Country in 2019
Figure 90. Mexico Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 91. Mexico Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Brazil Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Brazil Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Argentina Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Argentina Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Latin America Hypereosinophilic Syndrome Drug Market Share by Type in 2019
Figure 97. Latin America Hypereosinophilic Syndrome Drug Market Share by Application in 2019
Figure 98. Middle East and Africa Hypereosinophilic Syndrome Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 99. Middle East and Africa Hypereosinophilic Syndrome Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa Hypereosinophilic Syndrome Drug Sales Market Share by Country in 2019
Figure 101. Middle East and Africa Hypereosinophilic Syndrome Drug Revenue Market Share by Country in 2019
Figure 102. Turkey Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 103. Turkey Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Saudi Arabia Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E Hypereosinophilic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. U.A.E Hypereosinophilic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Middle East and Africa Hypereosinophilic Syndrome Drug Market Share by Type in 2019
Figure 109. Middle East and Africa Hypereosinophilic Syndrome Drug Market Share by Application in 2019
Figure 110. North America Hypereosinophilic Syndrome Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 111. North America Hypereosinophilic Syndrome Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Europe Hypereosinophilic Syndrome Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. Europe Hypereosinophilic Syndrome Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Asia Pacific Hypereosinophilic Syndrome Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Asia Pacific Hypereosinophilic Syndrome Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Latin America Hypereosinophilic Syndrome Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Latin America Hypereosinophilic Syndrome Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Middle East and Africa Hypereosinophilic Syndrome Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Middle East and Africa Hypereosinophilic Syndrome Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Porter's Five Forces Analysis
Figure 121. Channels of Distribution
Figure 122. Distributors Profiles
Figure 123. Bottom-up and Top-down Approaches for This Report
Figure 124. Data Triangulation
Figure 125. Key Executives Interviewed

---